As of Nov 19, 2026, 2 of 2 active firms rate IPHA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IPHA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.11 – $-0.11 · 1 analysts
Next period, 1 analysts expect Innate Pharma to earn $-0.11 a share (range $-0.11 – $-0.11), versus — a year earlier. Full-year consensus is $-0.19, growing to $-0.47 the year after.
REVENUE · NEXT QUARTER
$1.8M
Range $1.8M – $1.8M · 1 analysts
Revenue is expected to reach $1.8M (range $1.8M – $1.8M). Full-year consensus is $47.5M, rising to $89.3M next year.
Top analysts covering Innate Pharma
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IPHA.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$7.00+600.0% to target
Overall win rate
38%
+ Follow
#2
Daina Graybosch
Leerink Partners · Rank #396
Buy
$4.00+300.0% to target
Overall win rate
41%
+ Follow
#3
Justin Zelin
BTIG · Rank #495
Buy
$8.00+700.0% to target
Overall win rate
30%
+ Follow
#4
JM
Jeet Mukherjee
BTIG
Buy
$9.00+800.0% to target
Coverage
—
+ Follow
#5
CL
Christopher Liu
Lucid Capital
Buy
$8.00+700.0% to target
Coverage
—
+ Follow
IPHA stock forecast FAQ
What is IPHA's average 12-month price target?+
The 2 active firms with a live target average $8.00 for Innate Pharma over the next 12 months, ranging from a $9.00 high to a $7.00 low, as of Nov 19, 2026.
Is IPHA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IPHA?+
The Street-high target is $9.00 (BTIG), and the Street-low is $7.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $8.00.
How many active Wall Street firms cover IPHA?+
2 active firms have a recognized rating on Innate Pharma as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IPHA?+
Among analysts who currently cover IPHA, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #321). Their current call is Buy with a $7.00 target.
What is Innate Pharma's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.11 – $-0.11) across 1 analysts. Full-year EPS is projected at $-0.19, rising to $-0.47 the following year.
How much revenue is Innate Pharma expected to report next quarter?+
Consensus revenue is $1.8M (range $1.8M – $1.8M). Full-year revenue is projected at $47.5M, growing to $89.3M next year.
Have analysts been upgrading or downgrading IPHA lately?+
As of Nov 19, 2026, 2 of 2 active firms rate IPHA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IPHA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.